DRUG DELIVERY AND ADMINISTRATION DEVICE
20220161010 ยท 2022-05-26
Inventors
Cpc classification
A61F13/2074
HUMAN NECESSITIES
International classification
Abstract
A device for the delivery and/or application of a therapeutic composition in a delivery form into the rectal and/or vaginal cavity, the device includes an externally wearable pad; a non-absorbent platform for receiving the delivery form of therapeutic composition; and a sheath joining the platform to the pad such that a user's finger can be received in the sheath.
Claims
1. A device for the delivery and/or application of a therapeutic composition in a delivery form into the rectal and/or vaginal cavity, the device comprising: an externally wearable pad; a non-absorbent platform for receiving the delivery form of therapeutic composition; and a sheath joining the platform to the pad such that a user's finger can be received in the sheath.
2. The device according to claim 1, wherein the therapeutic composition is a delivery form with a shape, and the platform comprises a receiving portion, the shape of which corresponds partially to the shape of the delivery form of the therapeutic composition.
3. The device according to claim 1, wherein the platform comprises a receiving portion which is adapted and configured to receive a predetermined amount of therapeutic composition.
4. The device according to claim 1, wherein the platform comprises an area of relatively greater rigidity.
5. The device according to claim 2, wherein the receiving portion is collapsible and/or reversible.
6. The device according to claim 1, wherein the platform comprises means for releasing the therapeutic composition.
7. The device according to claim 1, further comprising a removal string.
8. The device according to claim 1, wherein the pad comprises an absorbent layer facing, in use, the rectal or vaginal cavity and an impermeable layer facing, in use, away from the rectal or vaginal cavity.
9. The device according to claim 1, wherein the length of the sheath is substantially the same as the distance between the rectal or vaginal orifice a target area in the rectal or vaginal cavity.
10. A kit comprising a therapeutic composition in a delivery form and a device according to claim 1 for delivering and/or applying said delivery form of the therapeutic composition to a target area in the rectal or vaginal cavity.
11. The kit according to claim 10, wherein the therapeutic composition comprises an anti-fungal agent, an anti-microbial agent, an anti-inflammatory agent, a pain killer, a steroidal (NSAID) compound, a non-steroidal compound, and/or a hormone.
12. The use of the device according to claim 1, for the delivery and/or application of a therapeutic composition for the treatment of menorrhagia.
13. The use of the device according to claim 1, for the delivery and/or application of a therapeutic composition for fertility treatment.
Description
[0038] The invention will be further described with reference to the drawings and figures, in which
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051] Referring to
[0052] The non-absorbent platform 3 is located at the distal end of the sheath 4. Within the context of the present invention, the distal end is, in use, the end closest to the target area in the vaginal or rectal cavity and the proximal end is the end of the sheath 4 closest to the cavity orifice.
[0053] The primary function of the platform 3 is to provide a supporting surface for the therapeutic composition C and for the user to push said therapeutic composition C along the vaginal or rectal cavity. If the user was using a latex glove without a platform 3, the therapeutic composition C would move away from the user's fingertip and efficient and accurate delivery is not possible. The platform 3 also enable the user to maintain the therapeutic composition C at the target area in the vaginal or rectal cavity, and can act as an internal barrier to prevent the therapeutic composition C from becoming dislodged or leaking out of the cavity.
[0054] Preferably, the platform 3 comprises a material which is more rigid that the material of the sheath 4. The platform 3 may be made of or from a monolayer or a multilayer sheet structure. The material of the platform 3 may be the same material as that of the sheath 4 but which a thickness greater than the thickness of the material of the sheath 4 to impart relative rigidity. The platform 3 may comprise a multilayer structure comprising a structural layer to impart relative rigidity. A platform 3 of comparatively greater structural rigidity also facilitates the attachment of a string or cord 6.
[0055] The platform 3 comprises a receiving portion 5 or is capable of forming a receiving portion 5. The platform 3 may be arranged in a first configuration in which there is no receiving portion 5 (e.g. when it is reversed out in the delivery configuration at the target area in the cavity and/or in the retrieval configuration) and in a second configuration in which there is a receiving portion 5 (e.g. in the insertion configuration, when the therapeutic composition C is pushed along the vaginal or rectal cavity). In a preferred embodiment, the receiving portion 5 may be arranged in a receiving configuration in which it can contain a therapeutic composition C and in a delivery configuration in which the therapeutic composition C is ejected from the receiving portion 5.
[0056] The platform 3 and the receiving portion 5 can be made of the same non-absorbent material or different absorbent materials. In a preferred embodiment, the receiving portion 5 is integrally formed in and/or with the platform 3.
[0057] Preferably, the platform 3 and/or receiving portion 5 are made of a material which is rigid enough to allow the user to push the therapeutic composition C inside the receiving portion 5, and flexible enough to allow the user to push the therapeutic composition C out of the receiving portion 5. The platform 3 and the receiving portion 5 is preferably not so rigid as to injure the patient during the insertion and/or removal process. Preferably, the platform 3 and/or receiving portion 5 are made from a semi-flexible sheet of plastics material.
[0058] Where the therapeutic composition is in a fluid, liquid, granular or powder form, the shape and dimensions of the receiving portion 5 may be adjusted to receive the required amount/dosage of therapeutic composition C.
[0059] With reference to
[0060] With reference to
[0061] With reference to
[0062] The receiving portion 5 may be reversible (inside out) to free the therapeutic composition C from the receiving portion 5 (as shown in
[0063] A string or cord 6 may be attached to the platform 3 so as to pull the device 1 out of the cavity after use. The string 6 may also be used to collapse the walls of the receiving portion 5. The string 6 may be attached at a single point to the platform 3 or there may be a plurality of attachment points to facilitate manipulation of the device 1 and/or of the receiving portion 5.
[0064] The therapeutic composition C can be in a single solid delivery form, for example a tablet, capsule, pessary, suppository or the like. This solid form will have a specific shape and specific dimensions. With reference to
[0065] The sheath 4 is substantially cylindrical and extends from the non-absorbent platform 3 to the pad 2. Preferably, the sheath 4 is made of or comprises a sheet of polymeric biocompatible material. The sheath 4 is arranged and configured to receive a finger. A wide sheath 4 could be provided, however, if the sheath 4 is loose around the user's finger, then insertion becomes difficult. The sheath 4 is preferably extensible at least in the radial direction. An extensible sheath 4 may be provided to snuggly and comfortably fit the user's finger.
[0066] The length of the sheath 4 between the pad 2 (which remains outside the cavity) and the platform 3 may be adjusted depending on the therapeutic composition and/or the target area where the drug is to be delivered.
[0067] The pad 2 is joined to the sheath 4, more particularly at the second end of the sheath 4. The pad 2 comprises an aperture 10 to allow the user to insert his/her finger into the sheath 4. The pad 2 is substantially circular, oval, rectangular or any other suitable shape. The pad 2 can be a standard rectangular napkin or a small interlabial pad. In a preferred embodiment, the pad 2 is a flat-egg shaped.
[0068] The pad 2 comprises a first surface 2A comprising a layer or sheet of absorbent material. The first surface 2A faces, in use, the patient's cavity into which the therapeutic composition C is delivered. The pad 2 comprises a second surface 2B comprising a layer or sheet of impermeable material. The second surface 2B faces way, in use, the patient's cavity. The impermeable material of the pad 2 may be the same material as that of the sheath 4. The sheath 4 may extend through the aperture 10 and along the absorbent layer 2A so as to form the impermeable layer 2B.
[0069] The use of the device according to the present invention will be explained with reference to the figures, in particular
[0070] In use, the device 1 is positioned so that the absorbent surface 2A of the pad 2 is facing upwards and the impermeable surface 2B is facing downwards. The sheath 4 extends from the impermeable surface 2B of the pad 2 so that the platform 3 and its receiving portion 5 are located at the bottom thereof. Alternatively, the device 1 is position so that the absorbent surface 2A of the pad 2 is facing upwards and the impermeable surface 2B is facing downwards. The sheath 4 extends from the absorbent surface 2A of the pad 2 so that the platform 3 and its receiving portion 5 are located at the top thereof. In both starting configurations, the receiving portion 5 is in its delivery configuration, arranged to receive a therapeutic composition C therein.
[0071] The shape of the receiving portion 5 of the device 1 is selected based on the delivery form and shape of the therapeutic composition C. Where the composition C is in a delivery form with a specific shape, the shape and dimensions of the receiving portion 5 will correspond at least partially to the shape and dimensions of the delivery form, for example cylindrical in the case of a suppository. The receiving portion 5 is preferably made of an extensible material so as to secure the therapeutic composition C therein. Where the composition C is of indefinite shape, for example granules, creams, lotions, dispersions, gel and the like, the receiving portion 5 forms a receptacle, for example a cup- or bowl-shaped receptacle to receive the composition C therein. The receiving portion 5 is preferably made of a sufficiently rigid material so as to maintain its shape whilst containing the composition and pushing the platform 3 through the vaginal or rectal cavity. The receiving volume of the receiving portion 5 may be adjusted to contain the required amount of composition C for one application. The sheath 4 or receiving portion 5 may comprise a visual indication of the amount of composition C within the receiving portion 5, for example one or more lines or a graduated line.
[0072] The therapeutic composition C is positioned and secured within the receiving portion 5 in the sheath 4. The user inserts his/her finger inside the sheath 4 so that the sheath 4 extends from the absorbent side 2A of the pad 2. The user pushes the platform 3 so that the device 1 is inserted through the cavity orifice. The platform 3 is advanced along through the cavity until it reaches the target area where the composition C is to be delivered and applied. The length of the sheath 4 may be adjusted so that when the sheath 4 is fully extended, the platform 3 is positioned at the target area in the cavity. Because the therapeutic composition C is nested in the receiving portion 5, the user can easily and accurately guide the composition through the cavity.
[0073] At the target area, the therapeutic composition is released from the receiving portion 5. This may be effected for example by reversing the receiving portion 5 inside out so that the therapeutic composition is expelled from the receiving portion 5. Alternatively, the receiving portion 5 (or its walls) may be collapsed by pushing the platform 3 to the distal end of the sheath 4 or by using alternative means of collapsing the receiving portion 5 (or its walls). For example, one or more strings 6 may be coupled to the receiving portion 3 so as to remotely collapse the walls of the receiving portion 3 (e.g. by pulling the string 6 from outside the cavity).
[0074] In the case where the device 1 comprises a therapeutic composition C pre-positioned in a sealed receiving portion 5, the user inserts his or her finger in the sheath 4 and the sheathed finger into the cavity until the distal end of the sheath 4 reaches the target area. Pressure is applied with the finger onto the sealed composition C to break the seal, reverse the receiving portion, and release the therapeutic composition C.
[0075] Once delivered, the therapeutic composition C may be applied to the target area. The present invention is particularly advantageous in that the composition can be rubbed against the cavity walls to improve application to and absorption of the drug through the cavity walls. Tis can be done without the user soiling his/her finger.
[0076] The device 1 may be left in situ, so that the therapeutic composition C remains at the target area. The platform 3 act as an anchor and/or plug for example until the composition has dissolved and been absorbed.
[0077] Any excess fluid leaking from the cavity is absorbed by the absorbent surface 2A of the pad 2 which is located at the cavity orifice. The user's finger is protected from said fluids owing to the impermeable surface 2B of the pad 2.
[0078] The device 1 is removed either by pulling the pad 2 or the string 6. By pulling the string 6, the sheath 4 is reversed so that the soiled outer surface of the sheath 4 is now inside. The user can hold the device 1 by the unsoiled surface of the sheath 4 or the impermeable surface 2B of the pad 2, and dispose of the device 1.
[0079] The present invention is particularly useful in the delivery and application of therapeutic composition to relieve the symptoms of menorrhagia. Menorrhagia is a condition wherein women suffer from excessive bleeding at menstruation. This may be through heavy menstrual bleeding (80 ml or more) and/or prolonged menstrual periods (7 days or more). The causes of menorrhagia vary from hormonal imbalance, the use of an intrauterine birth control device to complications in pregnancy. Many treatments are available to alleviate the symptoms of menorrhagia, including: [0080] Non-steroidal and/or non/hormonal drugs, for example NSAIDs and painkillers can reduce bleeding; [0081] Hormonal drugs, for example contraceptive pills, or hormone coils for contraception, but some patients with menorrhagia might still want children; [0082] Surgery, where non-invasive treatments fail, for example endometrial ablation
[0083] For these patients who do not wish to use a contraceptive treatment or refuse surgery, the present invention offers a non-invasive treatment involving the delivery of non-hormonal drugs (for example pain killers) to treat the symptoms in situ. The present invention is particularly advantageous in that the treatment will be carried out during periods of heavy bleeding, when the application of medicine in the vaginal cavity will be particularly difficult and messy because of the abundance of bodily fluids. When the drug is delivered and applied, the sheath protects the patient's finger and enables the application and rubbing of the drug against the cavity walls. The external pad soaks in any bodily fluid exiting the cavity during the delivery and application of the drug.
[0084] The present invention is particularly useful in the context of fertility treatments, in particular treatments such as In-Vitro Fertilization (IVF), involving the administration of various drugs such as hormones and anti-coagulants, often as pessaries, tablets or injected (sub-cutaneous or intramuscular). The vast majority of IVF medications are self-administered and there is a need for simpler, more patient-friendly administration method, without compromising the delivery of the therapeutic composition.
[0085] During an IVF treatment, women will be required to take progesterone around three times a day. Progesterone cannot be taken orally because of bioavailability issues. In order to efficiently deliver the required amount of progesterone to the womb, the ingested amount would need to be high enough to cause undesirable side-effects. Another option is to inject progesterone in situ. However, it would be impractical, painful and expensive to inject progesterone into the vagina. The most common administration routes are vaginal suppositories inserted with a finger or using an applicator. In order to be effective, the suppository must remain in place to dissolve and be absorbed. However, in practice, the majority of the progesterone will leak out and it is therefore not possible to administer an accurate amount. It is also not possible to wear a tampon to prevent leakage, otherwise the progesterone will be absorbed by the tampon.
[0086] The present invention enables is an alternative to conventional rigid applicators and enables the comfortable and clean delivery and application of the suppository. The suppository can be maintained at the target area until it is fully dissolved and, since the finger is protected, the dissolved composition can be rubbed against the vaginal cavity to optimize drug delivery.
[0087] The present invention provides a device for the delivery and/or application of a therapeutic composition into the rectal or vaginal cavity. From the above description, it can be seen that the device is used as a drug inserter which enables the pain-free and hygienic delivery and application of an accurate amount of therapeutic composition to a target area.